Effect of citalopram in schizophrenia

Phase 3

Recruiting

Conditions: Schizophrenia.
Schizophrenia

Registration Number: IRCT20180619040161N1

Lead Sponsor: Oroumia University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 30

Inclusion Criteria

Diagnosis of Schizophrenia according to DSM5 criteria and clinical interview by psychiatrist
Age range 15-65 years
Ability to provide informed consent and cooperation with study procedures
At least, 5 years history of schizophrenia
Participants needed to be currently taking an Atypic antipsychotic agent for 6 month prior to study
Based on the HAM-D scale, having a score of less than 20

Exclusion Criteria

Patients under treatment with clozapin
Any sever mental disorder(major depressive disorder, psychotic symptoms, manic phase symptoms,…)
Renal, hepatic, thyroid, or hematological disorder; and any sever and chronic medical disorder
Pregnancy or lactation
Individuals on antidepressants treatment for other indications (Tricyclic antidepressant , MAO inhibitor ,Selective serotonine reuptake inhibitor,… )for 1 month prior to randomization
Prior history of convulsion , stroke and head trauma
History of mental retardation (IQ less than 70)
History of substance abuse or dependence within 6months prior to study participation (except nicotine or caffeine dependence)

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Severity of positive and negative symptom of Schizophrenia. Timepoint: Before intervention (first visit) ,the end of the fourth week (second visit),the end of the eighth week (third visit). Method of measurement: At each visit to the SANS and SAPS testing will be completed.

Secondary Outcome Measures